Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology and Arthritis Research UK Launch Joint ‘Call for Targets’

Published: Tuesday, September 03, 2013
Last Updated: Tuesday, September 03, 2013
Bookmark and Share
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of musculoskeletal conditions.

MRC Technology and Arthritis Research UK have announced a joint ‘call for targets’. The call aims to identify and fund projects focused on validation of potential small molecule or antibody targets in pathways important in the development or progression of musculoskeletal conditions.

The call to UK-based academic researchers seeks to fund target validation and proof of concept studies prior to initiating a full scale drug discovery project.

The joint action draws on MRC Technology’s expertise in translating novel, promising biology into lead stage therapeutics, and the management of associated intellectual property, combined with the experience Arthritis Research UK has in supporting academic research into all types of arthritis for better understanding of this and related conditions, and the development of new treatments.

Grants of up to £100,000 will be awarded by Arthritis Research UK to fund selected projects that demonstrate clear linkage between a target and an impact on disease.

Upon completion, projects will be evaluated for progression into MRC Technology’s Centre for Therapeutic Discovery (CTD) to generate small molecules or therapeutic antibodies against the targets. Interested researchers are asked to visit www.callfortargets.org/arthritisresearch.

Mike Johnson, Director of Corporate Partnerships at MRC Technology, said “We are very pleased to be working with Arthritis Research UK to help overcome the challenges of translating research and maximize opportunities for those affected by musculoskeletal conditions. The joint call will enable us to access novel targets as a critical step toward finding new treatments and in bringing MRC Technology scientists and academia together we hope to come a step closer to discovering new drugs for these debilitating conditions.”

Stephen Simpson, Director of Research Delivery and Health Promotion at Arthritis Research UK, said: “Our goal is to be at the forefront of international efforts to develop new treatments for arthritis and as such it is essential that we drive forward research aimed at improving the lives of people with these conditions. We’re delighted to be working with MRC Technology and capitalizing on their expertise in identifying targets that have the potential to become new therapies.”

Supporting technology transfer and IP management efforts, MRC Technology set up its drug discovery laboratories in order to bridge the gap between innovative, early stage academic research and the development of intellectual property suitable for licensing to industry for further development and commercialization.

De-risking novel targets by providing proof of concept and pharma-quality data packages fulfills a clear need in the drug discovery process.

The collaboration opens the MRC Technology laboratories up to a new source of targets from the arthritis research field.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Drug Royalties Monetised
MRC Technology monetises royalties on cancer drug Keytruda (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital.
Monday, July 18, 2016
MRC Technology Appoints Two New Members to Board of Trustees
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
Thursday, April 07, 2016
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
MRC Technology Appoints General Counsel and Company Secretary
Dr Edward Bliss will join MRCT on 16 March.
Wednesday, February 04, 2015
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases.
Tuesday, July 22, 2014
UCB and UK’s MRC Technology Sign Exclusive License Agreement
UCB to develop an antibody-based therapy for the treatment of fibrotic disease.
Friday, February 14, 2014
MRC Technology and Boston University Collaborate to Develop anti-IL-16 Antibody
Cytokine IL-16 implicated in inflammation and Ischaemic Reperfusion Injury.
Friday, October 11, 2013
MRC Technology and EMBLEM Collaborate to Streamline Drug Development
Initiative strengthens drug development and commercialization network.
Monday, April 15, 2013
MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
Antibody inhibits tumour angiogenesis, migration and invasion.
Wednesday, March 20, 2013
Scientific News
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Antibodies Block Norovirus’ Entrance into Cells
Scientists have uncovered a mechanism in the human body that targets and successfully blocks noroviruses.
Probe Detects Histone Modifications in Cells
Scientists have developed an antibody probe that can be used to monitor the dynamics of histone modification.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!